Claudio Attardo, PhD, MBA

Claudio Attardo, PhD, MBA has a diverse work experience in the fields of Fertility, Women's Health, Oncology, Polymer Chemistry, and Environmental Sustainability. In 2021, they began working at Spring Fertility as a Laboratory Supervisor and Senior Clinical Embryologist. From 2016 to 2020, they were Co-Founder and Sales Representative at DONOVO, where they achieved a customer satisfaction annual report of 97%, developed a strong network of national and international physicians, and exceeded 2018 sales target by 38%. In 2020, they were an EIT Health Starship Innovation Fellow at the European Institute of Innovation and Technology, where they developed a proven, action-based approach to find solutions to industry challenges, verified user requirements, and identified potentially unmet healthcare needs. From 2017 to 2020, they were International Relationship Manager and Embryologist at CRA Barcelona, where they led CRA's international expansion, built and managed strategic partnerships, created custom scientific presentations, and boosted the rate of customer retention by 38%. In 2020, they were a Medical Science Liaison (MSL) trainee, receiving an MSL certificate from the FSTP global online training. From 2015 to 2017, they were an Embryologist at Fundación Puigvert, where they conducted In Vitro Fertilization procedures and served as a clinical liaison between the IVF medical department and academy. From 2012 to 2015, they were a PhD Research Scientist at Hospital Clínic de Barcelona, where they discovered novel molecular biomarkers and therapeutic targets in the fertility field. From 2010 to 2012, they were a Research Scientist at Louisiana State University, where they developed methods for thermal frontal polymerization using acrylate systems and collaborated on a project exploring the effect of surfactant on the effective interfacial tension between miscible fluids. From 2008 to 2010, they were a Research Scientist at La Maddalena S.p.A. - Dipartimento Oncologico di III Livello, where they investigated the pathophysiological functions of the matrix metalloproteinases MMP2 and MMP9 in HER2-enriched breast cancer and explored the development of breast cancer resistance to the anti-HER2 monoclonal antibody Trastuzumab. In 2007, they were a Research Intern at ENEA, where they improved process flow for the anaerobic biodegradability of wastes via bio-methanation and oversaw a pilot experiment of a waste processing facility.

Claudio Attardo, PhD, MBA has a long history of education. Claudio obtained a Bachelor of Science in Biotechnology from the Università degli Studi di Palermo in 2004-2007. Claudio then went on to obtain a Master of Science in Biotechnology for Pharmaceutical Industry and Scientific Research from the same university in 2008-2011. In 2009-2010, they were a Research Fellow at Louisiana State University. Claudio then obtained a Doctor of Philosophy in Medicine from Universitat de Barcelona in 2012-2015. Most recently, they obtained a Master of Business Administration in Pharmaceutical MBA from ESAME PHARMACEUTICAL BUSINESS SCHOOL in 2020-2021. Additionally, they have obtained certifications in Design and Interpretation of Clinical Trials from The Johns Hopkins University in 2020 and Medical Science Liaison (MSL) certificate by "From SCIENCE to PHARMA" (FSTP) from from SCIENCE to PHARMA (FSTP) - MSL global online training in 2020.